Sign In
Last checked at 
30 Jun 2011 12:00
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009, and the sale of 2,175 ordinary shares of 1.5p each by a charitable trust of which a Director of the Company is a beneficiary.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors each increased their beneficial interests in the Company by 198 ordinary shares of 1.5p each. These shares were acquired on 1 April 2011, 11 April 2011, 10 June 2011 and 20 June 2011 at prices of 380p, 378p, 384p and 388p respectively.
Epistem was also notified on 29 June 2011 that earlier that day the Jeffrey G. Moore Charitable Remainder Unitrust, a U.S. based trust in which Dr. Jeffrey Moore, a Director of the Company, is a beneficiary, has been required under its trust rules to sell 15% of its aggregate holding and has therefore sold 2,175 ordinary shares of 1.5p each at a price of 369.75p per share.
Following these transactions, the current beneficial interests of the executive Directors are set out below:
Matthew Walls | 8,377 | (0.11%) |
Dr Catherine Booth | 982,732 | (12.39%) |
Dr Ged Brady | 2,732 | (0.03%) |
Dr Jeffrey Moore | 15,057 | (0.19%) |
John Rylands | 192,630 | (2.43%) |
For further details please contact:
Epistem Plc |
|
Matthew Walls, CEO | +44 161 606 7258 |
John Rylands, Finance Director | +44 161 606 7244 |
|
|
Peel Hunt LLP |
|
James Steel / Vijay Barathan | +44 20 7418 8900 |
Follow the stocks
